Actos (Pioglitazone) Compassionate Use and Expanded Access: How to Get It Cheaper

Does Pioglitazone Qualify for Compassionate Use or Expanded Access?

Pioglitazone does not qualify for compassionate use programs for its FDA-approved indication of type 2 diabetes. The FDA's expanded access (compassionate use) pathway exists specifically for investigational drugs or approved drugs being studied for a new, unapproved indication in patients who have no other options. Because pioglitazone received full FDA approval in August 1999 under NDA 021073, and because generic versions have been commercially available since 2012, no access barrier of the type that triggers expanded access exists for standard diabetes treatment.

However, the picture changes for off-label uses. Researchers are actively studying pioglitazone for metabolic dysfunction-associated steatotic liver disease (MAFLD, formerly NASH), polycystic ovary syndrome (PCOS), and prediabetes reversal. Patients seeking pioglitazone for those conditions outside an active clinical trial may, in theory, pursue individual patient expanded access. The FDA's expanded access regulations under 21 CFR Part 312 govern this process. [1]

When Expanded Access Could Theoretically Apply

The FDA defines three tiers of expanded access: individual patient access, intermediate-size population access, and widespread treatment protocols. For pioglitazone, an individual patient request would only be considered if:

• The patient has a serious or life-threatening condition (for example, biopsy-confirmed advanced MAFLD/NASH with bridging fibrosis).
• No comparable or satisfactory alternative therapy exists.
• The potential benefit justifies the potential risk.
• Providing the drug will not interfere with ongoing clinical trials.

Practically speaking, a prescribing physician would submit Form FDA 3926 to request individual patient expanded access for an off-label pioglitazone indication. The FDA approves the vast majority of such requests, with a median review time of one business day for emergency cases. [2]

Active Clinical Trials as an Access Route

Enrolling in a clinical trial is often the fastest legitimate pathway to accessing pioglitazone for a non-approved indication at no cost. As of early 2026, ClinicalTrials.gov lists multiple active trials investigating pioglitazone in NASH/MAFLD and PCOS. The PIVENS trial (NCT00063622, N=247) previously established that pioglitazone 30 mg/day for 96 weeks improved hepatocyte ballooning and steatosis scores compared to placebo (P<0.001), providing the evidentiary foundation for ongoing MAFLD research. [3] Patients with biopsy-confirmed MAFLD should ask their hepatologist about current enrollment opportunities before pursuing expanded access paperwork.

How to Get Pioglitazone Cheaper: A Practical Cost-Reduction Framework

Generic pioglitazone is already one of the least expensive oral antidiabetic agents available. Still, cost remains a barrier for uninsured and underinsured patients. The following layered approach addresses cost reduction from least to most administratively intensive.

Tier 1: Generic Substitution

The branded product Actos costs roughly $350, $500 per 30-day supply at retail without insurance. Generic pioglitazone from manufacturers including Mylan, Teva, and Aurobindo typically retails for $10, $25 per 30-day supply at chains like Walmart, Costco, and Kroger. Simply requesting the generic from your prescriber and pharmacist is the single highest-impact cost-reduction step.

Walmart's $4/$10 generic drug list includes pioglitazone 15 mg, 30 mg, and 45 mg tablets. Mark Cuban's Cost Plus Drugs (costplusdrugs.com) lists pioglitazone 30 mg at approximately $6 for 30 tablets as of late 2025.

Tier 2: Prescription Discount Cards and Coupons

GoodRx, RxSaver, and NeedyMeds aggregate pharmacy pricing and apply negotiated discounts at point of sale. GoodRx coupons for generic pioglitazone consistently bring the 30-day price below $15 at major chain pharmacies. These coupons cannot be combined with Medicare Part D or Medicaid but are freely available online or through mobile apps.

A critical detail: discount coupons are not insurance. Purchases made with a GoodRx coupon do not count toward your insurance deductible. Patients nearing their annual deductible maximum should run the math before defaulting to the coupon over their plan's pharmacy benefit.

Tier 3: Manufacturer Patient Assistance Programs

Takeda operates a patient assistance program for branded Actos through the Takeda Patient Assistance Program (TPAP). Eligibility criteria change periodically, but generally require:

• U.S. Residency and a valid prescription.
• Household income at or below 400% of the federal poverty level (roughly $60,240 for a single person in 2026).
• Lack of adequate prescription drug coverage.

Applications are submitted through Takeda's patient support line or through third-party enrollment services like NeedyMeds.org or RxAssist.org. Processing time ranges from two to four weeks. Because generic pioglitazone is already inexpensive, TPAP is most relevant for patients who specifically require branded Actos for a documented clinical reason (rare).

Tier 4: State Pharmaceutical Aid Programs

Approximately 38 states operate their own pharmaceutical assistance programs for residents who are elderly, disabled, or low-income. Programs such as New Jersey's PAAD (Pharmaceutical Assistance to the Aged and Disabled) and Pennsylvania's PACE card cover generic pioglitazone on their formularies. Eligibility thresholds and benefit structures vary widely by state. The National Conference of State Legislatures maintains a current directory. [4]

HSA and FSA Eligibility for Pioglitazone

Pioglitazone is unambiguously an HSA/FSA-qualified medical expense. This is straightforward.

Under IRS Publication 502, prescription medications used to treat a diagnosed medical condition qualify as medical expenses for health savings account (HSA) and flexible spending account (FSA) purposes. [5] Pioglitazone prescribed for type 2 diabetes, PCOS, or any other physician-diagnosed condition meets this standard.

How to Pay with HSA/FSA at the Pharmacy

Most major pharmacy chains accept HSA/FSA debit cards directly at the point of sale. If your card is declined (this can happen at smaller independent pharmacies that have not updated their inventory coding), pay out of pocket, retain the receipt, and submit a manual reimbursement claim through your HSA/FSA administrator.

HSA/FSA Combined with Discount Coupons

IRS rules do not prohibit using an HSA/FSA to pay for a discounted price obtained through a GoodRx coupon. You pay the discounted cash price using your HSA/FSA card, and the qualified medical expense documentation is the pharmacy receipt. Some HSA administrators have questioned this practice in the past, but the IRS has not issued guidance prohibiting it. Consult your plan administrator to confirm.

Contribution Limits in 2026

For 2026, the IRS HSA contribution limits are $4,300 for self-only coverage and $8,550 for family coverage (HDHP required). FSA limits are $3,300 for health FSAs. Maximizing contributions at the start of the plan year creates an immediate, accessible fund for prescriptions including pioglitazone. [6]

Pioglitazone for Off-Label Indications: MAFLD, PCOS, and Prediabetes

Understanding the evidence base for off-label use matters for patients who need to make the case for insurance coverage or expanded access.

MAFLD/NASH

The PIVENS trial (NCT00063622) remains the most cited evidence supporting pioglitazone in non-alcoholic steatohepatitis. Pioglitazone 30 mg/day over 96 weeks produced histologic improvement in 34% of patients versus 19% in the placebo group (P<0.04). [3] The American Association for the Study of Liver Diseases (AASLD) 2023 practice guidance acknowledges pioglitazone as an option for patients with biopsy-proven NASH and fibrosis. [7]

Despite this evidence, most commercial insurance plans require prior authorization for pioglitazone prescribed for MAFLD. The prescribing gastroenterologist or hepatologist typically needs to submit a letter of medical necessity citing histologic findings and failure of lifestyle intervention.

PCOS

Pioglitazone improves insulin sensitivity and reduces androgen excess in women with PCOS. A 2020 systematic review and meta-analysis in the Journal of Clinical Endocrinology and Metabolism (JCEM) covering 10 randomized controlled trials found that pioglitazone significantly reduced fasting insulin, free testosterone, and HOMA-IR versus placebo in women with PCOS. [8] The Endocrine Society's 2023 PCOS clinical practice guideline notes insulin sensitizers as a treatment option when first-line lifestyle modification fails. [9]

Insurance coverage for pioglitazone in PCOS is inconsistent. A prior authorization citing PCOS diagnosis codes (E28.2) and documented hyperinsulinemia or insulin resistance often succeeds, particularly if metformin has been tried and was not tolerated.

Prediabetes

The ACT NOW trial (N=602) showed that pioglitazone 45 mg/day reduced the risk of progression from prediabetes to type 2 diabetes by 72% over a median follow-up of 2.4 years compared to placebo (hazard ratio 0.28, 95% CI 0.16 to 0.49). [10] The ADA's 2025 Standards of Care in Diabetes include pioglitazone as a pharmacologic option for high-risk prediabetes when lifestyle intervention is insufficient, though metformin remains the preferred agent. [11]

Coverage for pioglitazone in prediabetes is the most difficult to obtain. Many plans classify this as experimental or investigational. A detailed prior authorization with ACT NOW trial data and individual patient risk stratification may shift some payers, but patients should be prepared for a possible denial and subsequent appeal.

Navigating Insurance Prior Authorization for Pioglitazone

Prior authorization (PA) requirements for pioglitazone vary by payer but are common when:

• The drug is prescribed for a non-diabetes indication.
• The plan requires step therapy (trial of metformin first).
• The prescriber selects branded Actos over generic pioglitazone.

Step Therapy and How to Satisfy It

Most commercial plans and Medicare Part D formularies place generic pioglitazone on Tier 1 or Tier 2, meaning it is covered without PA for type 2 diabetes. Step therapy requiring prior metformin use can be satisfied by documenting a metformin trial in the chart note, even if pioglitazone is now preferred due to renal function, GI intolerance, or other clinical factors.

Appealing a Denial

Under the ACA's internal and external appeal process, a patient has the right to appeal a coverage denial within 180 days. An attending physician letter citing peer-reviewed evidence (for example, PIVENS for NASH, ACT NOW for prediabetes) and individualized clinical reasoning substantially improves appeal success rates. The U.S. Department of Health and Human Services estimates that internal appeals succeed in approximately 39 to 59% of cases depending on plan type. [12]

Key Safety Considerations That Affect Access Decisions

Pioglitazone carries a boxed warning from the FDA: it must not be initiated in patients with symptomatic heart failure (NYHA Class III or IV). [13] This warning emerged partly from the PROactive trial (N=5,238), which showed that pioglitazone reduced the composite cardiovascular endpoint by 10% versus placebo but was associated with a higher rate of heart failure hospitalization (11% vs. 8%, P<0.007). [14]

Additional safety signals that prescribers and patients should discuss:

• Bladder cancer risk: The FDA added a warning in 2011 after a 10-year epidemiologic study suggested a modest association with bladder cancer after more than 12 months of use. The absolute risk increase remains small. Pioglitazone should not be used in patients with active bladder cancer. [13]
• Bone fractures: Pioglitazone reduces bone mineral density, particularly in women. The FDA safety communication from 2007 documents increased fracture risk in female patients across multiple TZD trials.
• Fluid retention and edema: Dose-dependent peripheral edema occurs in roughly 4 to 8% of patients and may precipitate heart failure in those with marginal cardiac function.

These safety considerations do not disqualify most patients from access programs, but they do require active monitoring and periodic reassessment of the benefit-risk balance. The FDA drug label for pioglitazone provides a full risk profile that prescribers should review before initiating treatment. [13]

Medicare Part D and Medicaid Coverage

Medicare Part D

Generic pioglitazone appears on virtually all Medicare Part D formularies, most commonly on Tier 1 (preferred generic) or Tier 2. The 2026 Medicare Part D redesign introduced a $2,000 out-of-pocket cap and eliminated the coverage gap (donut hole), making pioglitazone effectively low-cost for all Medicare Part D enrollees once the annual deductible is met. [15] Low-Income Subsidy (LIS/Extra Help) beneficiaries may pay as little as $0, $4.50 per prescription.

Medicaid

All state Medicaid programs cover generic pioglitazone. Preferred drug lists vary by state, and some states require prior authorization if a non-preferred agent is requested. Patients on Medicaid should request the generic formulation explicitly to avoid PA requirements.

Practical Steps Summary: Getting Pioglitazone at the Lowest Cost

The following sequence applies to most patients seeking affordable access to pioglitazone:

1. Ask your prescriber to write for generic pioglitazone (not branded Actos).
2. Compare prices at Walmart ($4 list), Costco, Cost Plus Drugs, and your local chain using GoodRx before filling.
3. If insured, verify your plan's formulary tier and deductible status before choosing cash-pay over insurance.
4. Use an HSA or FSA card to pay. Retain all receipts.
5. If uninsured and income-qualified, apply to the Takeda Patient Assistance Program or a state pharmaceutical aid program.
6. For off-label indications (MAFLD, PCOS, prediabetes), work with your physician to submit a prior authorization that cites relevant trial data.
7. If the PA is denied, file an internal appeal within 180 days and attach peer-reviewed evidence.

For a patient without insurance filling a 30-day supply of generic pioglitazone 30 mg at Walmart with a GoodRx coupon, the out-of-pocket cost is often under $10.